Gut microbiota: a novel target for traditional Chinese medicine in the treatment of HIV/AIDS immunological non-responders

Abstract

Despite effective antiretroviral therapy (ART), many individuals with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) achieve viral suppression but fail to fully restore cluster of differentiation 4 (CD4)⁺ T lymphocyte (CD4 cell) counts—a condition known as immunological non-response (INRs). INRs are associated with elevated health risks, including increased susceptibility to AIDS-related and non-AIDS-related complications. The pathogenesis of INRs remains incompletely understood, and no established therapeutic interventions exist, posing a major challenge in contemporary HIV/AIDS management. Emerging evidence indicates that INRs exhibit significant alterations in gut microbiota composition. Dysbiosis of the gut microbiota may contribute to persistent immune activation, cytokine imbalance, and cellular pyroptosis, all of which could impair immune reconstitution in people living with HIV/AIDS. Traditional Chinese medicine (TCM) has demonstrated potential immunomodulatory effects and is increasingly utilized in the management of INRs. Targeting the gut microbiota and elucidating the mechanisms by which TCM modulates this microbial ecosystem may offer new avenues for preventing and treating INRs. This review explores the interplay between gut microbiota and TCM, examines the association between gut dysbiosis and INRs, discusses the mechanistic pathways through which microbiota imbalance contributes to INRs development, and highlights how TCM interventions regulate gut microbiota to promote immune recovery. By focusing on the gut microbiota as a therapeutic interface, this article provides novel insights into TCM-based strategies for improving outcomes in INRs and supports the development of innovative treatment approaches.

Keywords

Human immunodeficiency virus (HIV) / Acquired immune deficiency syndrome (AIDS) / Immunological non-response (INRs) / Gut microbiota / Traditional Chinese medicine

Funding

This work was supported by the National Natural Science Foundation of China (No. 82274474).

Supporting information

Supporting information for this work can be obtained by contacting the corresponding authors via E-mail.

Declaration of competing interest

These authors have no conflict of interest to declare.

References

[1] Liu J, Ding C, Shi Y, et al. Advances in mechanism of HIV-1 immune reconstitution failure: understanding lymphocyte subpopulations and interventions for immunological nonresponders. J Immunol. 2024; 212(11):1609-1620. https://doi.org/10.4049/JIMMUNOL.2300777.

[2] Qian ZZ, Zhang YJ, Xie XL, et al. Efficacy and safety of traditional Chinese herbal medicine combined with HAART in the treatment of HIV/AIDS: a protocol for systematic review and meta-analysis. Medicine. 2021; 100(52):e28287. https://doi.org/10.1097/MD.0000000000028287.

[3] Zhao S, Li X, Wang Y, et al. Comparison of the immune enhancing activity and chemical constituents between imitation wild and cultivated Astragali Radix. Molecules. 2025; 30(4):923. https://doi.org/10.3390/MOLECULES30040923.

[4] Wu Z, Zhang W, Miao W, et al. The efficacy of Sijunzi on immune function in patients with gastrointestinal cancers after surgery: integrating systematic review and network pharmacology. Medicine. 2025; 104(6):e41419. https://doi.org/10.1097/MD.0000000000041419.

[5] Li XH, Li HY, Li CY, et al. Traditional Chinese medicine can improve the immune reconstruction of HIV/AIDS patients. AIDS Res Human Retroviruses. 2020; 36(4):258-259. https://doi.org/10.1089/AID.2019.0274.

[6] Li HM, Liu JZ. “Marrow” as the central therapeutic target. J Chin Med Mater Res. 2022; 40(1):1-6. https://doi.org/10.13193/j.issn.1673-7717.2022.01.001.

[7] Yang CL, Jin YT, Wu ZH, et al. Systematic review and meta-analysis of the clinical efficacy of traditional Chinese medicine in immune reconstitution failure in AIDS. Chin J Integr Tradit West Med. 2022; 42(9):1072-1079. https://doi.org/10.7661/j.cjim.20211123.255.

[8] Ke WJ, Chen Y, Lei ZE, et al. Investigation on improving immunologic reconstitution insufficiency using Diwu-Yanggan Capsules in AIDS patients. Front Pharmacol. 2024; 15:1485719. https://doi.org/10.3389/FPHAR.2024.1485719.

[9] Zhou SJ, Wang YL, Yuan HZ, et al. Efficacy of Shenling Baizhu Powder combined with antiretroviral therapy in the intervention of immune reconstitution failure with lung-spleen Qi deficiency syndrome in HIV/AIDS patients. J Med Forum. 2024; 45(8):811-815. https://doi.org/10.20159/j.cnki.jmf.2024.08.006.

[10] Song YB, Long H, Fu YH, et al. Observation on the efficacy of Tangcao Tablet in patients with immune reconstitution failure in AIDS. Chin J Dermatovenerol. 2024; 38(3):298-302. https://doi.org/10.13735/j.cjdv.1001-7089.202304102.

[11] Huang ZY, Zhu XH, Zou MY, et al. Application of Buzhong Yiqi Jiedu Decoction as an adjuvant to highly active antiretroviral therapy in AIDS patients with incomplete immune reconstitution. J Harbin Med Univ. 2022; 56(4):373-377. https://doi.org/10.20010/j.issn.1000-1905.2022.04.0373.

[12] Shi Y, Hu M, Wu J, et al. Association between gut microbiota in HIV-infected patients and immune reconstitution following antiretroviral therapy (ART). BMC Infect Dis. 2025; 25(1):666. https://doi.org/10.1186/S12879-025-10995-3.

[13] Liu ZB. Treating older patients with AIDS using traditional Chinese medicine combined with conventional Western medicine in China. Aging Dis. 2021; 12(8):1872-1878. https://doi.org/10.14336/AD.2021.0925.

[14] Liu YN, Liu ZB, Sang F, et al. Effects of Yi Aikang Capsule on intestinal flora and immune function in HIV/AIDS patients with immune reconstitution failure and lung-spleen Qi deficiency syndrome. Chin J Tradit Chin Med. 2022; 37(5):2729-2733.

[15] Lan YL, Zhang Y, Yang XY, et al. Observation and correlation analysis of the efficacy of traditional Chinese medicine in asymptomatic HIV-infected patients with deficiency constitution. Chin J Pharmacol Clin Chin Mater Med. 2024; 40(4):15-21. https://doi.org/10.13412/j.cnki.zyyl.2024.04.006.

[16] Yang Q, Yang XY, Peng X, et al. Effects of Jian Aikang Concentrated Pill combined with cART on gut and intestinal flora in HIV-infected patients. Chin J AIDS STD. 2024; 30(4):354-360. https://doi.org/10.13419/j.cnki.aids.2024.04.04.

[17] Xu QH, Wu X, Zheng HP, et al. Effects of artesunate on immune function and intestinal flora in HIV/AIDS patients with immune reconstitution failure after HAART. Acta Chin Med Pharmacol. 2022; 50(12):54-59. https://doi.org/10.19664/j.cnki.1002-2392.220274.

[18] Wu X. Clinical observation on the effect of traditional Chinese medicine in regulating intestinal flora to improve incomplete immune reconstitution in AIDS. Chin Acad Tradit Chin Med. 2021. https://doi.org/10.27658/d.cnki.gzzyy.2021.000109.

[19] Gao GJ, Li X, Dong JP, et al. Effects of artesunate tablets on the intestinal bacterial community structure of male HIV/AIDS patients based on high-throughput sequencing analysis. Chin J AIDS STD. 2021; 27(8):799-804. https://doi.org/10.13419/j.cnki.aids.2021.08.02.

[20] Xu QH, Chen SY, Li YP, et al. Preliminary exploration of the effects of traditional Chinese medicine on intestinal flora in HIV/AIDS patients with immune reconstitution failure based on 16S rDNA. Chin J AIDS STD. 2020; 26(11):1150-1153. https://doi.org/10.13419/j.cnki.aids.2020.11.02.

[21] Yang Q, Su C, Qing Y, et al. Study on the effects of traditional Chinese medicine on gut microbiota structure and immunity in HIV patients. Sichuan J Tradit Chin Med. 2023; 41(12):82-89. https://doi.org/10.3969/j.issn.1000-3649.2023.12.sczy202312023.

[22] Gao GJ. Effects of moxibustion on immune function and intestinal flora diversity in 200 AIDS patients with incomplete immune reconstitution. Chin Acad Tradit Chin Med. 2022. https://doi.org/10.27658/d.cnki.gzzyy.2022.000111.

[23] Ahluwalia B, Magnusson MK, Öhman L. Mucosal immune system of the gastrointestinal tract: maintaining balance between the good and the bad. Scand J Gastroenterol. 2017; 52(11):1185-1193. https://doi.org/10.1080/00365521.2017.1349173.

[24] Mao K, Baptista AP, Tamoutounour S, et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature. 2018; 554(7691):255-259. https://doi.org/10.1038/nature25437.

[25] Chen J, Xu C, He Q, et al. Tupistra chinensis polysaccharides remitted intestinal inflammation induced by LPS via regulating gut microbiota. 3 Biotech. 2025; 15(11):378. https://doi.org/10.1007/S13205-025-04554-5.

[26] Salami TA, Akpamu U, Echendu PN, et al. Crohn’s colitis-induced alterations in colonic morphology, immunology, and microbiota are modulated by potassium bromate in experimental rats. Adv Gut Microbi Res. 2025; 2025(1): 3195642. https://doi.org/10.1155/AGM3/3195642.

[27] Cavarelli M, Scarlatti G. HIV-1 infection: the role of the gastrointestinal tract. Am J Reprod Immunol. 2014; 71(6):537-542. https://doi.org/10.1111/aji.12245.

[28] Armstrong AJS, Shaffer M, Nusbacher NM, et al. An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men. Microbiome. 2018; 6(1):198. https://doi.org/10.1186/s40168-018-0580-7.

[29] Lu D, Zhang JB, Wang YX, et al. Association between CD4⁽⁺⁾ T cell counts and gut microbiota and serum cytokines levels in HIV-infected immunological non-responders. BMC Infect Dis. 2021; 21(1):742. https://doi.org/10.1186/s12879-021-06491-z.

[30] Dolo O, Coulibaly F, Somboro AM, et al. The human gut microbiome and its metabolic pathway dynamics before and during HIV antiretroviral therapy. Microbiol Spectr. 2025; 13(8):e0220524. https://doi.org/10.1128/SPECTRUM.02205-24.

[31] Liu YN, Li PY, Sang F, et al. Analysis of immune function and gut microbiota changes in HIV/AIDS patients with different immune levels after ART. Chin J Dermatovenerol. 2025; 39(2):194-201. https://doi.org/10.13735/j.cjdv.1001-7089.202208207.

[32] Supram SH, Indira B, Niranjan N, et al. Low rate of gut colonization by extended-spectrum β-lactamase producing Enterobacteriaceae in HIV infected persons as compared to healthy individuals in Nepal. PLoS One. 2019; 14(2):e0212042. https://doi.org/10.1371/journal.pone.0212042.

[33] Guo XY, Guo YT, Wang ZR, et al. Severe intestinal barrier damage in HIV-infected immunological non-responders. Heliyon. 2023; 9(10):e20790. https://doi.org/10.1016/j.heliyon.2023.e20790.

[34] Tincati C, Merlini E, Braidotti P, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4⁺ T-cell recovery upon virologically suppressive combination antiretroviral therapy. AIDS. 2016; 30(7):991-1003. https://doi.org/10.1097/QAD.0000000000001015.

[35] Somsouk M, Estes JD, Deleage C, et al. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015; 29(1):43-51. https://doi.org/10.1097/QAD.0000000000000511.

[36] Qing Y, Xie H, Su C, et al. Gut microbiome, short-chain fatty acids, and mucosa injury in young adults with human immunodeficiency virus infection. Dig Dis Sci. 2019; 64(7):1830-1843. https://doi.org/10.1007/s10620-018-5428-2.

[37] Negi N, Singh R, Sharma A, et al. Comparative evaluation of microbial translocation products (LPS, sCD14, IgM Endocab) in HIV-1 infected Indian individuals. Microb Pathog. 2017; 111:331-337. https://doi.org/10.1016/j.micpath.2017.08.004.

[38] Tavenier J, Margolick JB, Leng SX. T-cell immunity against cytomegalovirus in HIV infection and aging: relationships with inflammation, immune activation, and frailty. Med Microbiol Immunol. 2019; 208(3-4):289-294. https://doi.org/10.1007/s00430-019-00591-z.

[39] Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4⁺ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003; 187(10):1534-1543. https://doi.org/10.1086/374786.

[40] Shive CL, Freeman ML, Younes SA, et al. Markers of T cell exhaustion and senescence and their relationship to plasma TGF-β levels in treated HIV⁺ immune non-responders. Front Immunol. 2021; 12:638010. https://doi.org/10.3389/fimmu.2021.638010.

[41] Massanella M, Negredo E, Pérez-Alvarez N, et al.CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010; 24(7):959-968. https://doi.org/10.1097/QAD.0b013e328337b957.

[42] Zhen L, Ping Y, Rui W, et al. Persistent T cell proliferation and MDSCs expansion precede incomplete CD4⁺ T cell recovery in people with acute HIV-1 infection with early ART. Heliyon. 2023; 9(5):e15590. https://doi.org/10.1016/J.HELIYON.2023.E15590.

[43] Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015; 211(1):19-27. https://doi.org/10.1093/infdis/jiu409.

[44] Xu H, Ou Z, Zhou Y, et al. Intestinal mucosal microbiota composition of patients with acquired immune deficiency syndrome in Guangzhou, China. Exp Ther Med. 2021; 21(4):391. https://doi.org/10.3892/etm.2021.9822.

[45] Rocafort M, Noguera-Julian M, Rivera J, et al. Evolution of the gut microbiome following acute HIV-1 infection. Microbiome. 2019; 7(1):73. https://doi.org/10.1186/s40168-019-0687-5.

[46] Pither MD, Silipo A, Molinaro A, et al. Extraction, purification, and chemical degradation of LPS from gut microbiota strains. Methods Mol Biol. 2023; 2613:153-179. https://doi.org/10.1007/978-1-0716-2910-9_13.

[47] Tincati C, Douek DC, Marchetti G. Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016; 13:19. https://doi.org/10.1186/s12981-016-0103-1.

[48] Ciesielska A, Matyjek M, Kwiatkowska K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell Mol Life Sci. 2021; 78(4):1233-1261. https://doi.org/10.1007/s00018-020-03656-y.

[49] Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology. 2017; 151(4):363-374. https://doi.org/10.1111/imm.12760.

[50] Colorado BSA, Lazzaro A, Neff PC, et al. Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe. Microbiome. 2024; 12(1):18. https://doi.org/10.1186/S40168-023-01718-4.

[51] Russo E, Nannini G, Sterrantino G, et al. Effects of viremia and CD 4 recovery on gut “microbiome-immunity” axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy. World J Gastroenterol. 2022; 28(6):635-652. https://doi.org/10.3748/wjg.v28.i6.635.

[52] Stiksrud B, Lorvik KB, Kvale D, et al. Plasma IP-10 is increased in immunological non-responders and associated with activated regulatory T cells and persisting low CD4 counts. J Acquir Immune Defic Syndr. 2016; 73(2):138-148. https://doi.org/10.1097/QAI.0000000000001080.

[53] Quiros M, Nishio H, Neumann PA, et al. Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. J Clin Invest. 2017; 127(9):3510-3520. https://doi.org/10.1172/JCI90229.

[54] Georgia AN, Claudine NE, Carole SN, et al. Regulatory T cells modulate monocyte functions in immunocompetent antiretroviral therapy-naïve HIV-1 infected people. BMC Immunol. 2024; 25(1):68. https://doi.org/10.1186/s12865-024-00654-8.

[55] Agraib LM, Yamani MI, Rayyan YM, et al. The probiotic supplementation role in improving the immune system among people with ulcerative colitis: a narrative review. Drug Metab Pers Ther. 2021; 37(1):7-19. https://doi.org/10.1515/DMDI-2021-0150.

[56] Supriya R, Suneela D. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives. World J Gastroenterol. 2023; 29(14):2078-2100. https://doi.org/10.3748/WJG.V29.I14.2078.

[57] Geng ST, Zhang JB, Wang YX, et al. Pre-digested protein enteral nutritional supplementation enhances recovery of CD4⁽⁺⁾ T cells and repair of intestinal barrier in HIV-infected immunological non-responders. Front Immunol. 2021; 12:757935. https://doi.org/10.3389/fimmu.2021.757935.

[58] Xia C, Zhang X, Harypursat V, et al. The role of pyroptosis in incomplete immune reconstitution among people living with HIV: potential therapeutic targets. Pharmacol Res. 2023; 197:106969. https://doi.org/10.1016/j.phrs.2023.106969.

[59] Bandera A, Masetti M, Fabbiani M, et al. The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery. Front Immunol. 2018; 9:214. https://doi.org/10.3389/fimmu.2018.00214.

[60] Lao X, Mei X, Zou J, et al. Pyroptosis associated with immune reconstruction failure in HIV-1-infected patients receiving antiretroviral therapy: a cross-sectional study. BMC Infect Dis. 2022; 22(1):867. https://doi.org/10.1186/s12879-022-07818-0.

[61] Carvalho-Silva WHV, Andrade-Santos JL, Souto FO, et al. Immunological recovery failure in cART-treated HIV-positive patients is associated with reduced thymic output and RTE CD4⁺ T cell death by pyroptosis. J Leukoc Biol. 2020; 107(1):85-94. https://doi.org/10.1002/JLB.4A0919-235R.

[62] Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014; 505(7484):509-514. https://doi.org/10.1038/nature12940.

[63] Dong T, Huang D, Jin Z. Mechanism of sodium butyrate, a metabolite of gut microbiota, regulating cardiac fibroblast transdifferentiation via the NLRP3/Caspase-1 pyroptosis pathway. J Cardiothorac Surg. 2024; 19(1):208. https://doi.org/10.1186/s13019-024-02692-0.

[64] Sharma D, Kanneganti TD. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol. 2016; 213(6):617-629. https://doi.org/10.1083/jcb.201602089.

[65] Zhou CB, Fang JY. The role of pyroptosis in gastrointestinal cancer and immune responses to intestinal microbial infection. Biochim Biophys Acta Rev Cancer. 2019; 1872(1):1-10. https://doi.org/10.1016/j.bbcan.2019.05.001.

[66] Liu D, Tian Q, Liu K, et al. Ginsenoside Rg3 ameliorates DSS-induced colitis by inhibiting NLRP3 inflammasome activation and regulating microbial homeostasis. J Agric Food Chem. 2023 Online ahead of print. https://doi.org/10.1021/acs.jafc.2c07766.

[67] Sauce D, Larsen M, Fastenackels S, et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood. 2011; 117(19):5142-5151. https://doi.org/10.1182/blood-2011-01-331306.

[68] Nixon CC, Vatakis DN, Reichelderfer SN, et al. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood. 2013; 122(13):2195-2204. https://doi.org/10.1182/blood-2013-04-496950.

[69] Tsukamoto T. HIV impacts CD34⁽⁺⁾ progenitors involved in T-cell differentiation during coculture with mouse stromal OP9-DL1 cells. Front Immunol. 2019; 10:81. https://doi.org/10.3389/fimmu.2019.00081.

[70] Menkova-Garnier I, Hocini H, Foucat E, et al. P2X7 receptor inhibition improves CD34 T-cell differentiation in HIV-infected immunological nonresponders on c-ART. PLoS Pathog. 2016; 12(4):e1005571. https://doi.org/10.1371/journal.ppat.1005571.

[71] Wang SS, Cai JY, Shi AW, et al. Effects of intestinal microbial homeostasis on the hematopoietic system in a neonatal rat model of necrotizing enterocolitis. Chin J Contemp Pediatr. 2023; 25(8):855-863. https://doi.org/10.7499/j.issn.1008-8830.2301082.

[72] Elgarten CW, Tanes C, Lee JJ, et al. Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer. 2022; 69(1):e29384. https://doi.org/10.1002/pbc.29384.

[73] Bansal R, Park H, Taborda CC, et al. Antibiotic exposure, not alloreactivity, is the major driver of microbiome changes in hematopoietic cell transplantation. Transpl Cell Ther. 2022; 28(3):135-143. https://doi.org/10.1016/j.jtct.2021.12.015.

[74] Chen C, Wang J, Xun J, et al. Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV. BMC infectious diseases. 2024; 24(1):97. https://doi.org/10.1186/S12879-024-08985-Y.

[75] Rosado-Sánchez I, Herrero-Fernández I, Genebat M, et al. Thymic function impacts the peripheral CD4/CD8 ratio of HIV-infected subjects. Clin Infect Dis. 2017; 64(2):152-158. https://doi.org/10.1093/cid/ciw711.

[76] Guedes SCM, Silva CVHW, Santos ALJ, et al. HIV-induced thymic insufficiency and aging-related immunosenescence on immune reconstitution in ART-treated patients. Vaccines. 2024; 12(6):612. https://doi.org/10.3390/VACCINES12060612.

[77] Ferrando-Martinez S, De Pablo-Bernal RS, De Luna-Romero M, et al. Thymic function failure is associated with human immunodeficiency virus disease progression. Clin Infect Dis. 2017; 64(9):1191-1197. https://doi.org/10.1093/cid/cix095.

[78] RB-Silva R, Nobrega C, Azevedo C, et al. Thymic function as a predictor of immune recovery in chronically HIV-infected patients initiating antiretroviral therapy. Front Immunol. 2019; 10:25. https://doi.org/10.3389/fimmu.2019.00025.

[79] Briceño O, Chávez-Torres M, Peralta-Prado A, et al. Associations between recent thymic emigrants and CD4⁺ T-cell recovery after short-term antiretroviral therapy initiation. AIDS. 2020; 34(4):501-511. https://doi.org/10.1097/QAD.0000000000002458.

[80] Menglin C, Hong Y, Huizi T, et al. Impact of Bifidobacterium longum NSP001 on DSS-induced colitis in conventional and humanised mice. Food Sci Hum Wellness. 2023; 12(4):1109-1118. https://doi.org/10.1016/J.FSHW.2022.10.028.

[81] Hebbandi NR, Sokke UC, Geuking MB. The impact of the gut microbiota on T cell ontogeny in the thymus. Cell Mol Life Sci. 2022; 79(4):221. https://doi.org/10.1007/s00018-022-04252-y.

[82] Zegarra-Ruiz DF, Kim DV, Norwood K, et al. Thymic development of gut-microbiota-specific T cells. Nature. 2021; 594(7863):413-417. https://doi.org/10.1038/s41586-021-03531-1.

[83] Alexis Y, Mboumba RB, Petronela A, et al. Immuno-metabolic control of the balance between Th17-polarized and regulatory T-cells during HIV infection. Cytokine Growth Factor Rev. 2023; 69:1-13. https://doi.org/10.1016/J.CYTOGFR.2023.01.001.

[84] Guo YT, Guo XY, Fan LN, et al. The imbalance between intestinal Th17 and Treg cells is associated with an incomplete immune reconstitution during long-term antiretroviral therapy in patients with HIV. Viral Immunol. 2023; 36(5):331-342. https://doi.org/10.1089/VIM.2023.0017.

[85] Li D, Tao H, Tan X, et al. Gut microbiota and their metabolites ameliorate acute and chronic colitis in mice via modulating Th17/Treg balance. Front Microbiol. 2025; 16:1643209. https://doi.org/10.3389/FMICB.2025.1643209.

[86] Azzam S, Schlatzer D, Maxwell S, et al. Proteome and protein network analyses of memory T cells find altered translation and cell stress signaling in treated human immunodeficiency virus patients exhibiting poor CD 4 recovery. Open Forum Infect Dis. 2016; 3(2):ofw037. https://doi.org/10.1093/ofid/ofw037.

[87] Zhenwu L, Zhen L, Lisa M, et al. Increased natural killer cell activation in HIV-infected immunologic non-responders correlates with CD4⁺ T cell recovery after antiretroviral therapy and viral suppression. PLoS One. 2017; 12(1):e0167640. https://doi.org/10.1371/journal.pone.0167640.

[88] Ha B, Cao X. Gut microbiota-specific T cell subset drives CNS inflammation. Trends Immunol. 2025;S1471- 4906(25):200-205. https://doi.org/10.1016/J.IT.2025.08.002.

[89] Ma Z, Wang Z, Cao J, et al. Regulatory roles of intestinal CD4⁺ T cells in inflammation and their modulation by the intestinal microbiota. Gut Microbes. 2025; 17(1):2560019. https://doi.org/10.1080/19490976.2025.2560019.

[90] Zhen JH, Li YN, Zhang YN, et al. Shaoyao Decoction reduced T lymphocyte activation by regulating of intestinal flora and 5-hydroxytryptamine metabolism in ulcerative colitis. Chin Med. 2024; 19(1):87. https://doi.org/10.1186/S13020-024-00958-2.

[91] Chen F, Yin YT, Zhan HM, et al. Sishen Pill treatment of DSS-induced colitis via regulating interaction with inflammatory dendritic cells and gut microbiota. Front Physiol. 2020; 11:801. https://doi.org/10.3389/fphys.2020.00801.

[92] Zhang LX, Song JW, Zhang C, et al. Dynamics of HIV reservoir decay and naïve CD4 T-cell recovery between immune non-responders and complete responders on long-term antiretroviral treatment. Clin Immunol. 2021; 229:108773. https://doi.org/10.1016/j.clim.2021.108773.

[93] Zhang GH, Han JB, Zhu L, et al. Aikeqing decreases viral loads in SHIV89.6-infected Chinese rhesus macaques. Chin Med. 2016; 11:31. https://doi.org/10.1186/s13020-016-0105-x.

[94] Wei QL, Huang ZX, Wei L, et al. Observation of the efficacy of early combination of traditional Chinese medicine intervention with antiretroviral therapy in AIDS patients. Chin J AIDS STD. 2016; 22(3):207-208. https://doi.org/10.13419/j.cnki.aids.2016.03.18.

[95] Sun XB, Xie ZP, Wu Z, et al. Mechanisms of HIV-immunologic non-responses and research trends based on gut microbiota. Front Immunol. 2024; 15:1378431. https://doi.org/10.3389/fimmu.2024.1378431.

[96] Gou H, Su H, Liu D, et al. Traditional medicine Pien Tze Huang suppresses colorectal tumorigenesis through restoring gut microbiota and metabolites. Gastroenterology. 2023; 165(6):1404-1419. https://doi.org/10.1053/j.gastro.2023.08.052.

[97] Zhou M, Liu Z, Shang Y. Study on the effect of traditional Chinese medicine regulating intestinal microecology on AIDS prevention and treatment. J Contemp Med Pract. 2025; 7(4):33-37. https://doi.org/10.53469/JCMP.2025.07(04).08.

[98] Gu W, Sun MJ, Wang LR, et al. Effects of four common Chinese medicinal herbs on immune function and intestinal flora in immunosuppressed mice. Chin Anim Husb Vet Med. 2019; 46(1):147-156. https://doi.org/10.16431/j.cnki.1671-7236.2019.01.017.

[99] Ma C. Exploration of prescription rules in traditional Chinese medicine for treating HIV/AIDS immunological non-responders based on data mining and clinical research on Shenling Guben Formula. Chin Acad Tradit Chin Med. 2023. https://doi.org/10.27658/d.cnki.gzzyy.2023.000026.

[100] Tao Z, Dong JP, Guo HJ, et al. Effects of artesunate tablets on immune reconstruction failure in HIV/AIDS patients after ART. Chin J AIDS STD. 2021; 27(9):921-925. https://doi.org/10.13419/j.cnki.aids.2021.09.03.

[101] Yu HC, Meng YY, Wang EK, et al. Mechanism of Buzhong Yiqi Decoction in improving spleen deficiency syndrome through gut microbiota regulation. Chin J Chin Mater Med. 2024; 49(4):1028-1043. https://doi.org/10.19540/j.cnki.cjcmm.20231013.701.

[102] Ding X, Fan L, Xu L, et al. Clinical applications and therapeutic mechanisms of Chinese herbal medicine Yi Aikang Capsules in treating acquired immune deficiency syndrome. Infect Drug Resist. 2025; 18:3317-3327. https://doi.org/10.2147/IDR.S526449.

[103] Zhao ML, Wang Q, Liu BB, et al. Experimental study on Yi Aikang combined with antiretroviral therapy in the treatment of SIV-infected rhesus macaque AIDS models. Liaoning J Tradit Chin Med. 2023; 50(3):193-199. https://doi.org/10.13192/j.issn.1000-1719.2023.03.054.

[104] Yang YQ, Fang L, He ZZ, et al. Preliminary study on the effect of traditional Chinese medicine intervention on serum diamine oxidase and lipopolysaccharide in HIV-infected individuals. Yunnan J Tradit Chin Med Mater Med. 2014; 35(4):10-11. https://doi.org/10.16254/j.cnki.53-1120/r.2014.04.040.

[105] Mohamed A, Zungu Y, Shalekoff S, et al. Innate immune dysfunction and persistent activation in South African HIV elite controllers. Front Immunol. 2025; 16:1603436. https://doi.org/10.3389/FIMMU.2025.1603436.

[106] Meng P, Zhang G, Ma X, et al. Traditional Chinese medicine (Xielikang) reduces diarrhea symptoms in acquired immune deficiency syndrome (AIDS) patients by regulating the intestinal microbiota. Front Microbiol. 2024; 15:1346955. https://doi.org/10.3389/FMICB.2024.1346955.

[107] Sang F, Li Q, Qian JY, et al. Protective effects of Yi Aikang Capsule on intestinal mucosal barrier injury in HIV/AIDS by affecting permeability and tight junctions. Chin J Emerg Tradit Chin Med. 2018; 27(5):769-772. https://doi.org/10.3969/j.issn.1004-745X.2018.05.005.

[108] Yao JY, Deng BW, Li CC, et al. Effects of Yi Aikang Capsule on tight junctions and related proteins Claudin-1 and Claudin-5 in intestinal mucosal barrier injury induced by IFN-γ. Chin J Hosp Pharm. 2020; 40(8):897-901. https://doi.org/10.13286/j.1001-5213.2020.08.12.

[109] Jia M, Yuan M, Zhu X, et al. Evidence of honey-processed Astragalus polysaccharides improving intestinal immune function in spleen Qi deficiency mice integrated with microbiomics and metabolomics analysis. J Sci Food Agric. 2024; 105(4):2158-2168. https://doi.org/10.1002/JSFA.13986.

[110] Sung H, Kang MS, Lee SM, et al. Korean red ginseng slows depletion of CD4 T cells in human immunodeficiency virus type 1-infected patients. Clin Diagn Lab Immunol. 2005; 12(4):497-501. https://doi.org/10.1128/CDLI.12.4.497-501.2005.

[111] Zhang YX, Saeid K, Han SY, et al. Ginseng extracts improve circadian clock gene expression and reduce inflammation directly and indirectly through gut microbiota and PI3K signaling pathway. NPJ Biofilms Microbiomes. 2024; 10(1):24. https://doi.org/10.1038/S41522-024-00498-5.

[112] Yuan H, Xu G, Liu J, et al. Astragalus mongholicus polysaccharides alleviate insulin resistance through modulation of PI3K/AKT, TLR4/NF-κB signaling pathway and microbiota in rats with Type 2 diabetes mellitus. J Tradit Complement Med. 2024; 15(3):274-285. https://doi.org/10.1016/J.JTCME.2024.05.007.

[113] Zhu HB, Chen S, Chen YY, et al. Effects of the traditional Chinese medicine compound extract HNA-1 on thymic output function in chronically SIV-infected Chinese rhesus monkeys. Chin J Integr Tradit West Med. 2016; 36(3):351-358. https://doi.org/10.7661/CJIM.2016.03.0351.

[114] Wang XM, Chen S, Chen YY, et al. Effects of the traditional Chinese medicine compound extract HNA-1 on thymic output and thymocyte development in chronically SIV-infected rhesus monkeys. J Hunan Univ Tradit Chin Med. 2016; 36(4):6-10. https://doi.org/10.3969/j.issn.1674-070X.2016.04.002.

[115] Yang L, Fang Z, Zhu J, et al. The potential of Sijunzi Decoction in the fight against gastrointestinal disorders: a review. Front Pharmacol. 2025; 16:1464498. https://doi.org/10.3389/FPHAR.2025.1464498.

[116] Zhang QQ, Meng JL, Guo HJ. Clinical observation on treating 67 cases of HIV/AIDS from the spleen perspective. J Henan Univ Tradit Chin Med. 2007; 3:1-2. https://doi.org/10.16368/j.issn.1674-8999.2007.03.002.

[117] Chen W, Xu XK, Lyu YH, et al. Research advances in chemical constituents of Danggui Buxue Decoction and its hematopoietic function. J Navy Med Univ. 2023; 44(5):609-615. https://doi.org/10.16781/j.cn31-2187/r.20220003.

[118] Cao ZH, Pan JH, Li N, et al. Research progress on the modern pharmacological effects and mechanisms of Shengmai Powder. Chin J Exp Tradit Med Formulae. 2019; 25(22):212-218. https://doi.org/10.13422/j.cnki.syfjx.20192208.

[119] Wei Z, Xu LR. Effects of Yi Aikang Capsule on immune function in immunodeficient mice induced by murine leukemia virus. Chin J Gerontol. 2015; 35(10):2615-2617. https://doi.org/10.3969/j.issn.1005-9202.2015.10.008.

[120] Yang QQ. Effects of Tangcao Tablet on zidovudine-induced bone marrow suppression in mice. Zhengzhou Univ. 2020. https://doi.org/10.27466/d.cnki.gzzdu.2020.003935.

[121] Lou YF, Cai SX, Hu XN, et al. Analysis of clinical research evidence on traditional Chinese medicine for immune reconstruction failure in AIDS. Chin J AIDS STD. 2024; 30(3):253-258. https://doi.org/10.13419/j.cnki.aids.2024.03.06.

[122] Zhang XX, Hu XN, Luo LL, et al. Analysis of outcome indicators in randomized controlled trials of traditional Chinese medicine for the treatment of HIV/AIDS. Chin J AIDS STD. 2024; 30(6):584-590. https://doi.org/10.13419/j.cnki.aids.2024.06.05.

[123] Gong YF, Liu ZB. Focusing on clinical intervention studies of traditional Chinese medicine in AIDS. Chin J Dermatovenerol. 2022; 36(8):865-871. https://doi.org/10.13735/j.cjdv.1001-7089.202111080.

[124] Wang J, Zou W. Practices, challenges, and opportunities: HIV/AIDS treatment with traditional Chinese medicine in China. Front Med. 2011; 5(2):123-126. https://doi.org/10.1007/s11684-011-0124-z.

[125] Xie LJ, Zhao YW, Duan JY, et al. Integrated proteomics and metabolomics reveal the mechanism of nephrotoxicity induced by triptolide. Chem Res Toxicol. 2020; 33(7):1897-1906. https://doi.org/10.1021/acs.chemrestox.0c00091.

[126] Zhang Q, Li Y, Liu M, et al. Compatibility with Panax notoginseng and Rehmannia glutinosa alleviates the hepatotoxicity and nephrotoxicity of Tripterygium wilfordii via modulating the pharmacokinetics of triptolide. Int J Mol Sci. 2018; 19(1):305. https://doi.org/10.3390/ijms19010305.

[127] Kong LL, Zhuang XM, Yang HY, et al. Inhibition of P-glycoprotein gene expression and function enhances triptolide-induced hepatotoxicity in mice. Sci Rep. 2015; 5:11747. https://doi.org/10.1038/srep11747.

[128] Thio J, Haig A, Swe PPE, et al. Artemisinin-induced cholestatic liver injury and intrahepatic ductopenia. Oxf Med Case Rep. 2024; 2024(7):omae070. https://doi.org/10.1093/OMCR/OMAE070.

[129] Shao BP, Yang LY, Li Q, et al. A decade of application review for Tangcao Tablet, an adjuvant therapy drug for AIDS. Chin J AIDS STD. 2017; 23(10):978-979. https://doi.org/10.13419/j.cnki.aids.2017.10.31.

[130] Yang YF, Fu XT, Xia B, et al. Glycyrrhizic acid glycosides reduces extensive tripterygium glycosides-induced lipid deposition in hepatocytes. Heliyon. 2023; 9(7):e17891. https://doi.org/10.1016/J.HELIYON.2023.E17891.